Research
Hormonal
A growing number of new agents acting on incretin hormones are becoming available for clinical practice.
Clinicians should stay informed about new pharmacological options for treating obesity and T2DM.
StrongSupportsmedium confidence
A growing number of new agents acting on incretin hormones are becoming available for everyday clinical practice.
Why this rating
The abstract discusses the emergence of new pharmacological agents.
Source
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek et al. · Biomedicines · 2024
DOI 10.3390/biomedicines12061320
reviewCited 35×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →